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Abstract
Background—The American College of Obstetricians and Gynecologists and the American 
Psychiatric Association both recommend pharmacotherapy for perinatal depression when the 
benefits outweigh the risks. While minority adults are less likely to use antidepressant medications 
compared to Non-Hispanic Whites, whether this pattern occurs among pregnant women is unclear.
Objective—We sought to determine the frequency of antidepressant medication use reported 
during ambulatory care visits for pregnant women and whether these rates varied by race.
Methods—We combined the 2006–2010 National Ambulatory Medical Care Survey (NAMCS) 
and the National Hospital Ambulatory Medical Care Survey (NHAMCS) to obtain nationally 
representative estimates of outpatient preventive care visits for pregnant women. We then obtained 
estimates of the prevalence of reported depression and antidepressant use during outpatient visits 
for pregnant women. To determine whether these estimates varied by race, we used multivariable 
logistic regression analyses accounting for survey design using SAS 9.2 (PROC 
SURVEYLOGISTIC) to estimate odds ratios of reported antidepressant use after adjustment for 
age, insurance status and region of the country.
Results—Antidepressant use was reported during 2.2% of all outpatient visits for pregnant 
women. Providers indicated a depression diagnosis in 4.5% of visits. Among visits for depressed 
pregnant women, providers reported antidepressant use 25.4% of the time for all visits. 
Antidepressant use during pregnancy varied significantly by race/ethnicity. Among visits for Non-
Hispanic White women, 3.1% included a code for antidepressant use vs. just 1.0% for Non-White 
women (P<0.0001). After adjustment for age, insurance status, and region of the country, this 
association persisted with Non-Hispanic White (vs. Non-White) pregnant women having higher 
odds of antidepressant use (adjusted OR 3.3, 95% CI 2.1, 5.3).
Conclusion—Non-Hispanic White women were more likely than Non-White women to be using 
antidepressants during pregnancy. Whether differences in antidepressant use by race/ethnicity 
indicates over-treatment of non-Hispanic White women or under-treatment of minorities remains 
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unclear. This disparity warrants investigation with the goal of optimizing maternal mental health 
while minimizing potential adverse sequelae of antidepressants on developing fetuses.
Keywords
pregnancy; perinatal depression; antidepressants; race; ethnicity; disparities; selective serotonin 
reuptake inhibitors; SSRI
Introduction
While depression affects approximately one in ten adults in the United States,1 rates of 
depression among women while pregnant and post-partum are even higher, ranging from 
14–23% during pregnancy,2 and 8–19% post-partum.3 It is also estimated that 15.4% of 
women experience depression during at least one pregnancy phase.4 Given the social stigma 
associated with depression and antidepressant use,5 these figures likely underrepresent the 
true prevalence of perinatal depression.6 Recently, public health and clinical agencies have 
developed initiatives to screen women for depression during the course of pre- and peri-natal 
care to prevent the negative consequences of depression for both mothers and their infants. 
Perhaps because of increased awareness and depression diagnoses, more providers are 
prescribing antidepressants for pregnant women than in previous years.7
Antidepressant use during pregnancy, however, remains highly controversial. The American 
Psychiatric Association (APA) advise psychotherapy as the first line of treatment for mild to 
moderate depression and pharmacotherapy as the standard of care for severe perinatal 
depression.8 The American College of Obstetricians and Gynecologist (ACOG) concurs.8 
Both bodies recommend balancing the benefits to the mother with potential risks to the fetus 
and newborn.8 Potential risks of antidepressant use during pregnancy include miscarriage, 
birth defects, low birthweight, preterm birth, pre-eclampsia, cardiac abnormalities, including 
persistent pulmonary hypertension, neonatal withdrawal syndrome, and other long term 
neurodevelopmental abnormalities,8, 9, 10, 11 although the absolute risks of such sequelae are 
relatively low.12, 13, 14, 15 Other therapies such as psychotherapy would be equally effective 
in treating mild to moderate depression,16 and, thus avoid risk of potential fetal harm,17 but 
resources may not be available for such approaches18. In spite of concerns for fetal toxicity 
of antidepressants, in 2003, approximately 13% of women were taking antidepressants 
during pregnancy.19 Additionally, antidepressant use during pregnancy is rising with a 
recent analysis of the Centers for Disease Control and Prevention’s (CDC) National 
Ambulatory Medical Care Survey (NAMCS) and the National Hospital Medical Care 
Survey (NHAMCS) reporting threefold increase between 2002–2006 and 2007–2010.7
Whether rates of antidepressant use in pregnancy are uniform across the population has not 
been studied. While Black, Hispanic and Asian/Pacific Islander women have been reported 
to be less likely to have access to and seek care for depression,20 these minority groups have 
a higher rate of maternal depression compared to non-Hispanic White women.21, 22, 23 Black 
women are also more likely to experience stigma associated with depression compared to 
Non-Hispanic White women.24 Given these barriers to depression diagnoses, our hypothesis 
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was that during the course of prenatal care, minority women were more likely to be taking 
antidepressants.
Methods
Survey Design
The NAMCS and the NHAMCS are national probability sample surveys administered by the 
CDC in outpatient ambulatory medical care settings.25 NAMCS collects data on outpatient 
office-based clinics and community health centers whereas NHAMCS data is collected from 
hospital outpatient departments and emergency departments. These surveys are completed 
by non-federally employed physicians involved in direct patient care as described 
previously.26 Each patient visit is assigned an inflation factor to allow for national estimates 
of outpatient visits when appropriate weights are applied. The primary units of analysis are 
health care visits. We used visits for pregnant women, and combined the two data sources 
because outpatient office settings as well as hospital-based clinics provide most of prenatal 
care visits in the United States. Visits to emergency departments (a subset of NHAMCS) 
were excluded from the analysis. To obtain a sample size with ample power we combined 
the data for 2006–2010. Starting in 2006, the CDC adopted a new drug coding scheme based 
on the drug’s generic component and therapeutic class using Lexicon Plus®27 instead of the 
NCHS-developed 5-digit code; therefore, data from 2006 to 2010 were selected for 
consistency.28 Per the guidelines published by the National Center for Health Statistics, 
estimates were considered to be reliable when relative standard errors were 30 percent or 
less, and if they were based on no fewer than 30 observations.29, 30 The Beth Israel 
Deaconess Medical Center Institutional Review Board (IRB) Committee deemed this study 
exempt from IRB review since it complied with federal policy as stated under Title 45 CFR 
46.101(b)(4).
Variable Selection
We identified visits for pregnant women using methods described previously with the 
addition of visits for women with high risk (V23) or complications during pregnancy 
(ICD-9-CM codes 640.0–646.0, 671.0 and NCHS-generated reason for visit code29, 30 
273.50).26, 31 Depression diagnoses were identified using the International Classification of 
Diseases, Clinical Modification, 9th Revision (ICD-9-CM) codes (296.20–296.26, 296.30–
296.36, 298.0, 296.82, 300.4, 309.0, 309.1, 311), reason for visit code for depression (111) 
and a checkbox indicator in the survey question, “Regardless of the diagnoses written 
(previously) does the patient now have depression?”
Visits where antidepressants were provided, prescribed or continued were identified using 
Lexicon Plus code for therapeutic drug category ‘249’ which codes for ‘Psychotherapeutic 
agents; antidepressants.’ These codes did not distinguish between the types of 
antidepressants, so once the cohort was generated, antidepressant type was identified using 
prescription codes, ‘208’, ‘209’, ‘250’, ‘306’, ‘307’, ‘308’, under the category of 
‘Psychotherapeutic agents; antidepressants.’ Among visits including prescribed 
antidepressants, a subset of visits indicated simultaneous antipsychotic use. We ensured that 
visits with antidepressant use included at least one of the antidepressant prescription codes 
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from above (‘208’, ‘209’, ‘250’, ‘306’, ‘307’, ‘308’) and not taking antipsychotics 
exclusively. Cognitive behavior therapy (CBT) was identified using a combination of reason 
for visit code ‘44100,’ diagnosis codes ‘V663-’, ‘V673-’ and “other procedure” codes 
(‘943-’, 9437’, ‘9438’, ‘9439’, ‘944-’, ‘9441’, ‘9442’, ‘9451’).
Race/ethnicity was the primary variable of interest. We classified race/ethnicity into four 
categories consisting of Non-Hispanic White, Non-Hispanic Black, Hispanic and Other. 
Asians and Pacific Islanders were included in the “Other” category due to small numbers. In 
the final analysis, we collapsed race/ethnicity into Non-Hispanic White (White) vs. Non-
White (which includes Non-Hispanic Black, Hispanic, and Other) in order to meet the 
reliability criteria since some racial/ethnic groups had fewer than 30 observations per cell. 
Additionally, the direction of the associations supported dichotomization of race/ethnicity.
We analyzed several potential confounding variables including patients’ age at the time of 
the visit (>25, 25–29, 30–34, >34), type of insurance (Private, Medicaid, Other), the region 
in the US where the visit took place (Northeast, Midwest, South, and West), and type of 
survey (NAMCS vs. NHAMCS).
Inclusion Criteria
Our sample population was restricted to visits for pregnant women between the ages of 11–
49 in order to exclude improbable ages for pregnancy (n=23).
Statistical Analyses
The average of the 2006–2010 combined patient weights were used in the PROC 
SURVEYFREQ/PROC SURVEYLOGISTIC procedures in SAS 9.2 (Cary, NC) to account 
for the complex study design and probability of sampling. Chi-square tests were performed 
to assess any bivariate relationships between each covariate and visits rates for depression, 
antidepressant use, and antidepressant use among depressed women. Multivariable logistic 
regression was performed to identify the relationship between race and depression among 
visits for all pregnant women, race and antidepressant use among visits for all pregnant 
women, and race and antidepressant use among visits for depressed pregnant women 
adjusting for covariates. P-values of <0.05 were considered to be significant.
Results
From 2006–2010 there were, on average, 37.8 million visits per year for pregnant women in 
outpatient settings. Among these visits, the prevalence of depression was 4.5% and 2.2% of 
all visits included a code for antidepressant use or prescription. Visits for White women had 
the highest rate of antidepressant use (3.1%) followed by non-Hispanic Black (1.6%) and 
Hispanic (0.8%) women (Table 1). Visits for White women also had the highest rates of 
depression (5.7% vs. 2.9% among Non-White women) (Figure 1). Of the visits for depressed 
White women, 28.3% included a code for antidepressant use, compared to just 18% among 
Non-White women. Reported antidepressant use during prenatal visits did not vary by 
maternal age or survey type (NAMCS vs. NHAMCS). Visits from the Western region were 
less likely to indicate antidepressant use during pregnancy. The majority (68%) of 
antidepressants used and prescribed were selective serotonin-reuptake inhibitors (SSRIs) 
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(Table 2). Providers reported the use of CBT very infrequently. Just 0.2% of all visits, 2.8% 
of the visits for depressed women, and 5.4% of the visits for women taking antidepressants 
included an indicator for CBT.
Differences by race/ethnicity for both depression and antidepressant use persisted after 
adjustment for potential confounding variables including maternal age, insurance type, 
region of the country, and survey type. Compared to visits for White women, prenatal visits 
for Non-White women had lower odds of reported depression (adjusted OR 0.5, 95% CI 0.4, 
0.7), antidepressant use (adjusted OR 0.3, 95% CI 0.2, 0.5), and antidepressant use while 
depressed (adjusted OR 0.5, 95% CI 0.3, 0.9) (Table 3). Visits paid for by Medicaid had 
higher odds of depression compared to those with private or other insurance types even after 
adjusting for race and antidepressant use (adjusted OR 1.8 95% CI 1.3, 2.6).
Discussion
We found marked differences in rates of provider-reported maternal depression diagnoses 
and antidepressant use by race during prenatal care. White women were both more likely to 
be diagnosed with depression and to be receiving pharmacotherapy during pregnancy. These 
findings have several potential implications. Given that the true rates of depression are likely 
higher among Non-White women,21, 22, 23, 24 it is likely that Non-White women are 
underdiagnosed with depression during pregnancy and potentially undertreated once 
diagnosed. Another possibility is that White women are being over-diagnosed and over-
prescribed antidepressants during pregnancy. Either way, there could be negative 
consequences to both mothers and their infants by undertreating mothers suffering from 
depression or negative consequences to fetuses unnecessarily exposed to potentially harmful 
medications.
In addition to the potential harms of undertreating mothers with depression (poor nutrition, 
substance use, suicide, and distress on infant development32, 33, 34, 35), there are particular 
risks that may disproportionately affect minorities compared to White mothers. One study 
assessed data from the Pregnancy Risk Assessment Monitoring System that included 3732 
women in New York City, found that having a diagnosis for prenatal depression not only 
increased the likelihood of a post-partum depression diagnosis across all racial groups but 
that Asian/Pacific Islander compared to Non-Hispanic White women were more likely to 
have post-partum depression after accounting for confounders.36 Taveras et al23 
prospectively studied 1826 mother-child pairs and found high rates of maternal depression 
to be a significant risk factor for offspring childhood obesity among racial/ethnic minorities.
Increasing the detection of depression during pregnancy may not be without adverse 
sequelae if it leads to more pharmacotherapy for depression during pregnancy. In a study of 
240 children between the ages of 3–6 years old, Nulman et al found that children exposed to 
SSRIs and SSNRIs during pregnancy had lower IQs and greater rates of problematic 
behaviors than children born to nondepressed mothers.37 An analysis of the Swedish 
Medical Birth Register from 1997–2005 found a 2.4 fold increase in persistent pulmonary 
hypertension risk in neonates born to mothers with reported SSRI use during pregnancy.38 A 
recent study by Clements et al found that prenatal antidepressant exposure was associated 
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with an 80% increased odds of ADHD even after controlling for maternal depression.39 
Domar et al reviewed studies pertaining to the effect of antidepressant use among depressed 
women experiencing infertility and found them to be associated with miscarriage, birth 
defects, preterm birth, newborn behavioral syndrome, persistent pulmonary hypertension of 
the newborn and long-term neurobehavioral effects.40 These authors concluded that 
providers should have adequate understanding of the literature on the risks of 
pharmacotherapy and recommend safer alternatives when possible.
Policy statements8 by ACOG and APA recommend balancing the risks and benefits to the 
mother and fetus before starting pharmacotherapy for depression. However, such a task 
remains exceedingly difficult, given the paucity of randomized controlled trials of 
antidepressant use in pregnancy as highlighted by a recent metanalysis on this issue.41 
However, one key aspect of these policy statements is that the recommendations include 
pharmacotherapy “for depression.” Our analysis suggests that women without depression are 
also receiving antidepressants. It is possible that women were well-controlled on their 
medications and thus the providers did not consider them “depressed” and omitted a code 
for depression. Alternatively, it is possible that women were receiving antidepressants for 
other diagnoses, such as anxiety, where the indication for treatment in pregnancy may be 
less clear. When the harm of not using medication and the benefits of medication are less 
certain, other therapies should be considered. While CBT has been shown to be effective for 
controlling depression,42 we found little evidence of its widespread use in pregnancy with 
just 0.2% of women receiving CBT. CBT may be a safe, effective therapy in treating 
depression without the potential fetal toxicity antidepressants confer.
Our study is unique in its focus on racial/ethnic disparities in depression and antidepressant 
use among pregnant women on a national scale. Our findings are consistent with a recent 
study of pregnant women using the NAMCS and NHAMCS databases which found an 
antidepressant prescription rate of 2.1%, depression diagnosis rate of 4.2% and reported that 
the majority of the visits involving antidepressants were for White women.7 Their rates are 
consistent with our analysis but are much lower than the reported prevalence of prenatal 
depression reported by other studies which range from 14 to 23%.2, 4 This is likely due to 
two factors. First, studies designed to specifically evaluate the prevalence of a condition use 
screening tools to capture women at risk. Yonkers et al used multiple assessment tools, 
including the Edinburgh Postnatal Depression Scale, the Inventory of Depressive 
Symptomatology and the Structured Clinical Interview for DSM-IV (Diagnostic and 
Statistical Manual of Mental Disorders, 4th Edition, Text Revision) to detect a depression 
rate of 6.5–8.5% in women during the postpartum period.43 NAMCS and NHAMCS rely on 
provider diagnostic codes which will miss women who might meet criteria based on a 
screening tool that a provider is not using in his or her office. Second, there may be 
underreporting of true diagnoses by missed codes on the data reporting form. In either case, 
we would not expect misclassification to vary by race or ethnicity and while the rates may 
not be generalizable to the population, the differences between groups remain important.
Contrary to studies based on screening or direct assessment,21, 22, 23 however, we found that 
visits for White women had the higher reported or diagnosed depression rates compared to 
Non-White women. We also found that among all visits for pregnant and depressed pregnant 
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women, White women were more likely to be prescribed antidepressants compared to all 
other race/ethnicities. However, our study is consistent with Shen et al.’s findings from the 
2006 National Inpatient Sample in which pregnant minority women had lower odds of 
depression at the time of their hospital delivery compared to White women.44 Our data do 
elucidate whether this finding is explained by cultural differences in seeking help for mental 
health disorders, or variability in access to mental health professionals, but we speculate that 
both explanations are probable. We found that visits for Medicaid patients were more likely 
to include depression diagnosis after controlling for race but antidepressant use was not 
increased. We speculate that this might be a result of differences of prescription coverage by 
state,45 but state-level data from NAMCS and NHAMCS are not available.
The primary strength of our study is the use of a large national database that enabled us to 
obtain national estimates by applying appropriate weights. There are several limitations 
inherent to observational studies including residual unmeasured confounding as well as 
measurement error and misclassification. While we speculate that cultural differences may 
contribute to variation in diagnostic and prescription practices by race/ethnicity or region, 
the datasets used does not permit further conclusions. The unit of analysis is the outpatient 
visit for NAMCS/NHAMCS so the national estimates represent frequencies of given 
diagnoses or treatment by visit and not by individual. Given the sampling design, the same 
individual is not likely to be sampled twice, but it is important to keep in mind that the 
denominator for this analysis is not pregnancies but pregnancy visits. Given the visit is the 
unit of analysis, this study only includes women who were pursuing prenatal care. Race/
ethnicity was recorded by the provider and was not necessarily self-reported by the patient. 
This type of misclassification would likely be random and not a source of bias. A potential 
source of bias is the healthy user bias,46 in which, White women could be more likely to 
utilize the healthcare system than other racial/ethnic groups due to socioeconomic status or 
cultural practices. However, because prenatal care is one period of time during which 
women almost uniformly pursue medical care, this is not likely a major source of bias in this 
study.
Conclusion
We found that during pregnancy, outpatient visits for White women had greater odds of 
reported depression and antidepressant use compared to non-White women. Whether this is 
a case of under-diagnosis and under-prescribing antidepressants for Non-White women or 
over-diagnosis and over-prescribing antidepressants for White women remains unknown. 
Regardless, variation in practice between groups may shed light on how to optimize 
screening for potentially depressed women as well as finding ways to promote 
antidepressant stewardship among pregnant women who might safely avoid antidepressants. 
Furthermore, providers might improve the mental health care of pregnant women by 
collecting data on the prevalence of depression and therapies offered to ensure equitable 
care.
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Figure 1. 
Proportion of provider-reported depression and antidepressant use during visits for pregnant 
women by race/ethnicity
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Table 2
Antidepressant use by class among pregnant women, NAMCS/NHAMCS 2006–2010.
Name Weighted %
Selective serotonin reuptake inhibitors (SSRI) 68.3%
Selective serotonin-norepinephrine reuptake inhibitors (SSNRI) 10.6%
Phenylpiperazine 2.7%
Tricyclic 2.1%
Tetracyclic 0.7%
Miscellaneous 17.4%
*Note: percentages do not add up to 100% because some patients are taking multiple drugs simultaneously.
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Table 3
Odds of antidepressant use among visits for pregnant women and depressed pregnant women
Visits for pregnant women Visits for depressed pregnant women
Adjusted* OR (95% CI) Adjusted* OR (95% CI)
Race/Ethnicity
 White*** Ref Ref
 Non-White 0.3 (0.2, 0.5) 0.5 (0.3, 0.9)
Age categories
 < 25 0.7 (0.4, 1.2) 0.9 (0.4, 1.9)
 25 – 29 Ref Ref
 30 – 34 0.9 (0.5, 1.6) 0.6 (0.3, 1.5)
 > 34 0.7 (0.4, 1.4) 1.5 (0.7, 3.4)
Insurance status
 Other** 1.7 (0.9, 3.0) 2.1 (0.6, 7.1)
 Private Ref Ref
 Medicaid 1.0 (0.5, 2.0) 1.0 (0.6, 1.8)
Region
 Northeast Ref Ref
 Midwest 1.2 (0.7, 2.3) 1.2 (0.6, 2.4)
 South 1.2 (0.6, 2.5) 0.9 (0.4, 2.1)
 West 0.5 (0.2, 1.1) 0.4 (0.2, 0.7)
Survey
 NAMCS 1.0 (0.7, 1.5) 1.6 (0.8, 3.0)
 NHAMCS Ref Ref
*
Models mutually adjusted for all listed variables.
**Other = Medicare, worker’s compensation, self-pay, no charge and other
***
Race was collapsed to White vs. Non-White due to small sample sizes within Non-White groups (<30).
(White includes non-Hispanic White; Non-White includes Non-Hispanic Black, Hispanic, Other)
Ref=Reference, OR=Odds Ratio, CI=Confidence Interval, NAMCS=National Ambulatory Medical Care Survey, NHAMCS=National Hospital 
Ambulatory Medical Care Survey
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